Post-endoscopic retrograde cholangiopancreatography pancreatitis: Mechanistic pathways, diagnostic benchmarks, and emerging and mitochondria-targeted therapies

doi:10.4240/wjgs.v17.i11.110551

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-3)

Sum=0

Nov 27, 2025 (publication date) through Nov 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Surg. Nov 27, 2025; 17(11): 110551
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.110551

Open in New Tab Full Size Figure Download Figure

Figure 1 Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis. Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis includes patient-related risk factors, procedure-related risk factors, endoscopist-associated factors and genetic and metabolic factors. ERCP: Endoscopic retrograde cholangiopancreatography; SNP: Single-nucleotide polymorphism; SOD: Sphincter of Oddi dysfunction; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis; BD: Bile duct.

Open in New Tab Full Size Figure Download Figure

Figure 2 Prevention strategies for post-endoscopic retrograde cholangiopancreatography pancreatitis. MDT: Multidisciplinary team; ERCP: Endoscopic retrograde cholangiopancreatography; NSAID: Non-steroidal anti-inflammatory drug; EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography.

Citation: Zhao WY, Zhao JW, Yu L, Yu ZY. Post-endoscopic retrograde cholangiopancreatography pancreatitis: Mechanistic pathways, diagnostic benchmarks, and emerging and mitochondria-targeted therapies. World J Gastrointest Surg 2025; 17(11): 110551
URL: https://www.wjgnet.com/1948-9366/full/v17/i11/110551.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i11.110551